Printer Friendly

SYMPHONY PHARMACEUTICALS APPOINTS FORMER ICI EXECUTIVE TO MANAGEMENT TEAM

 PHILADELPHIA, Aug. 23 /PRNewswire/ -- Symphony Pharmaceuticals, Inc. today announced it has appointed Mort E. Goldberg, D.Sc, as executive vice president, clinical development. Dr. Goldberg has 33 years experience at some of the nation's top pharmaceutical companies, including ICI, Squibb, Warner Lambert and Abbott.
 "Mort has a wealth of senior management experience in drug discovery, development and approval and an excellent understanding of the molecular implications of novel compounds," said Maria-Luisa Maccecchini, Ph.D., Symphony founder and CEO. "His background is a tremendous asset as Symphony works to develop and commercialize its technology."
 At Symphony, Dr. Goldberg will be responsible for clinical development and will assist in the leadership of Symphony's R&D efforts and business development activities. Dr. Goldberg headed research, development and regulatory affairs at ICI for 14 years as vice president. In this capacity, he was responsible for a staff of 700. Prior to joining, ICI, Dr. Goldberg was director of pharmacology at the Squibb Institute for Medical Research. Dr. Goldberg has been associated with the discovery and development of several therapeutic agents in the central nervous system, cardiovascular, oncology and antibiotic areas.
 "I am very excited about converting Symphony's technology into meaningful and important therapeutic agents," said Dr. Goldberg.
 Dr. Goldberg has a D.Sc. in pharmacology from the Philadelphia College of Pharmacy and Science. He has published extensively in the neuropharmacology area and has held several positions in scientific societies and on boards of companies. He is also professor of pharmacology at the University of Pennsylvania School of Medicine and adjunct professor at The Medical College of Pennsylvania.
 "Symphony has now completed its research and development management team," said Dr. Maccecchini. "This distinguished and accomplished group includes Dr. Mort Goldberg, Dr. Michael Lewis, Cephalon's co-founder and senior science director, who is now our vice president, research and Dr. Saul Cherkofsky, a 22-year pharmaceutical veteran from Du Pont and Du Pont Merck, who is our vice president, pharmaceutical development."
 Symphony, founded in 1992, is a private biopharmaceutical company focusing on the discovery and development of novel drugs to regulate the flow of electricity through ion channels in the brain. The company has targeted its initial drug development efforts on stroke, trauma, depression and addiction. Symphony's technology can also be applied to anxiety, epilepsy, memory loss and learning disabilities as well as Huntington's, Alzheimer's and Parkinson's diseases.
 -0- 8/23/93
 /CONTACT: Maria-Luisa Maccecchini, Ph.D., chief executive officer of Symphony Pharmaceuticals, Inc., 215-640-4870, or Anthony J. Russo, of Noonan/Russo Communications, 212-696-4455/


CO: Symphony Pharmaceuticals, Inc. ST: Pennsylvania IN: MTC SU: PER

CK-OS -- NY015 -- 4976 08/23/93 10:21 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 23, 1993
Words:435
Previous Article:BANCTEC ACQUIRES LPA, A PROVIDER OF ELECTRONIC PAYMENT SYSTEM SOFTWARE
Next Article:'CABIN FEVER' DISPUTE SETTLED
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters